What's hot

View all perspectives
What's Hot

JAK Safety -- The Lowdown on Infection: Drs. Kevin Winthrop and Jonathan Kay

Watch video →

RheumNow Rheumatology Roundup: Drs. Kavanaugh and Cush

Rheumatology Roundup! Drs. Cush and Kavanaugh convene for their annual impromptu review of some of the best and more interesting abstracts presented at ACR 2021.    

Watch video →

TNF Inhibitor Panel Discussion: ACR21 Annual Meeting

RheumNow TNFi faculty convened to discuss several TNFi-related abstracts presented at ACR 21. Panelists: Drs. Aurelie Najm, Janet Pope, David Liew, Eric Dein and Swetha Alexander. 

Watch video →

Spondyloarthritis Panel Discussion: ACR21 Meeting

Panelists: Drs. Antoni Chan, Robert Chao, Rachel Tate, Sheila Reyes and Akhil Sood. Abstracts discussed include #0562, #1919, #0907, #0364 and #0919

Watch video →

Might Tofacitinib Reduce Malignancy Risk with Patients with RA? Dr. Jonathan Kay

Dr. Kay discusses abstract 1940 and abstract 980 presented at the ACR21 annual meeting.

Watch video →

Diagnosing (Bad) VEXAS: The Experts Speak Drs. Beck and Ferrada

Dr. Cush discusses Dr. Marcela Ferrada and Dr. David Beck to discuss VEXAS syndrome and abstract 1426, which was presented at the ACR21 annual meeting.

Watch video →

Pediatric Psoriatic Arthritis: Dr. Eric Ruderman

Dr. Ruderman discusses abstracts #1424 presented at the ACR21 annual meeting.

Watch video →

Urine Proteome Advances: What Do They Mean? Dr. Michelle Petri

Dr. Petri reviews abstracts #1422 and #1936, presented at the ACR21 annual meeting.

Watch video →

ACR21 Day 3 Recap: Polypharmacy, New Lupus Drugs, VEXAS, Safety Data

Blurb: Drs. Jack Cush and the RheumNow Faculty Drs. Akhil Sood, Antoni Chan, Olga Petryna and Eric Dein, discuss highlights from Day 3 (Monday) at the ACR21 annual meeting. Abstracts include #1367, #1044, #1444, #1083 and more.

Watch video →

Cardiovascular Disease for TNFi vs JAKi: Dr Jon Giles

Dr. Giles discusses abstracts #0831and #0958 presented at the ACR21 annual meeting.

Watch video →

Predictors of TNF Response with Drs. Pope, Dein and Liew

Drs. Janet Pope, David Liew and Eric Dein discuss TNF data presented at the ACR21 annual meeting, including abstracts #1251, #1442, #1448.

Watch video →

Caring for the Older Patient with Rheumatic Disease: Drs. Makris, Yung and Dao

Drs. Kathryn Dao, Una Makris and Raymond Yung discuss the field of geriatric rheumatology and caring for the older patient with rheumatic disease.

Watch video →

Autoinflammatory: PAH in AOSD, VEXAS, JAKi in Still's, Role of labs in infections vs. flares

  Drs. Jack Cush, Yuz Yusof, Bella Mehta, Olga Petryna and Rachel Tate review autoinflammatory data presented at the ACR21 annual meeting, including abstracts #1100, #1062, #1426, #0252, #0195, and #1083.

Watch video →

FDA Session Review: Dr. Arthur Kavanaugh

Dr. Kavanaugh discussed the FDA session presented at the ACR21 annual meeting, including safety data and new approvals and indications in several rheumatic diseases, including lupus, ANCA-associated vasculitis, lupus nephritis and more.

Watch video →

The Respiratory Tract and RA with Drs. Sparks, McDermott and Kronzer

Drs. Jeffrey Sparks, Greg McDermott and Vanessa Kronzer discuss work in the area of respiratory disease in RA, mucosal paradigm, RA-ILD, bronchiectasis, as well as their experience as virtual attendees at the ACR21 annual meeting.

Watch video →

Pulmonary Hypertension in Adult Onset Still's Disease: Dr. Jack Cush

Dr. Cush reviews poster #1100 presented at the ACR21 annual meeting.

Watch video →

Data on Existing SLE Medications, Patient Centered Outcomes, and Exercise: Dr. Michelle Petri

Dr. Petri discusses data on existing SLE medications, patient-centered outcomes and the importance of exercise, presented Monday at the ACR21 annual meeting.

Watch video →

ACR21 Day 2 Recap: CV Risk, Tapering in SpA, Microbiome in PsA, Vit D

Drs. Jack Cush and the RheumNow Faculty Drs. David Liew, Swetha Ann Alexander, Meral El Ramahi, Mrinalini Dey and Robert Chao, discuss highlights from Day 2 (Sunday) at the ACR21 Virtual meeting.

Watch video →
      RT @RHEUMarampa: This slide 👇 from Dr. Mary Crow's lecture shows how 2 categories of autoantibodies with their distin

      sheila RHEUMarampa

      4 years ago
      This slide 👇 from Dr. Mary Crow's lecture shows how 2 categories of autoantibodies with their distinct functions can allow for different therapeutic targets in #lupus @RheumNow #ACR21 #rheumatology https://t.co/wkthvj21cE
      RT @synovialjoints: There is increase in ASDAS, BASDAI, CRP and faecal calprotectin levels although not reaching a clini

      Dr. Antoni Chan synovialjoints

      4 years ago
      There is increase in ASDAS, BASDAI, CRP and faecal calprotectin levels although not reaching a clinical flare in AS patients who had CZP stopped compared to those who continue CZP full or reduced dose @RheumNow #ACR21 Abst#0916 https://t.co/Wlwirs1QXF https://t.co/jE4smHMXBI
      RT @Yuz6Yusof: #ACR21 Hench Lecture. Wonderful talks by Peggy Crow on #lupus pathogenesis. Tour de force since LE cells

      Md Yuzaiful Md Yusof Yuz6Yusof

      4 years ago
      #ACR21 Hench Lecture. Wonderful talks by Peggy Crow on #lupus pathogenesis. Tour de force since LE cells discovery. Potential sources of self-nucleic acids: 💠Endogeneous retroelements LINE-1 💠Mitochondria 💠Cell-derived nuclear debris (NETs, apoptotic) @RheumNow https://t.co/TSdyqblYaA
      RT @uptoTate: Do you have trouble with no shows? Study out of Allegheny Health showed younger and black patients were a

      Dr. Rachel Tate uptoTate

      4 years ago
      Do you have trouble with no shows? Study out of Allegheny Health showed younger and black patients were among characteristics of pts at risk for new pt exam no shows. How can we do better for these pts? Thoughts? Abs 0610 #ACR21 #RheumNow @RheumNow https://t.co/MUcQarwvm6 https://t.co/Mue6By5mOV
      RT @uptoTate: In support of early dx and tx in AS! Study of AS pts treated with GLM: those w/ early dz showed sign/sympt

      Dr. Rachel Tate uptoTate

      4 years ago
      In support of early dx and tx in AS! Study of AS pts treated with GLM: those w/ early dz showed sign/symptom improvement compared to those w/ late dz. IV GLM better overall regardless of dz duration. Abs 0912 #ACR21 #RheumNow @RheumNow https://t.co/S2L97c7oQO https://t.co/XXpveRwwmQ
      RT @bella_mehta: Phase 3 observational extension study of Lorecivivint, intra-articular CLK/DYRK inhibitor that modulate

      Bella Mehta bella_mehta

      4 years ago
      Phase 3 observational extension study of Lorecivivint, intra-articular CLK/DYRK inhibitor that modulates Wnt and inflammatory pathways. Safety and tolerability. Efficacy at 6 and 12 month, but at 18month it disappeared @RheumNow #ACR21 abst#0729 https://t.co/9ycbVGKkmy
      RT @DrPetryna: Abst0919 #ACR21 @RheumNow Phase III COAST-V 52W (PBO)-controlled study examined the efficacy of IXE in pt

      Olga Petryna DrPetryna

      4 years ago
      Abst0919 #ACR21 @RheumNow Phase III COAST-V 52W (PBO)-controlled study examined the efficacy of IXE in pts with active AS. SF-36 bodily pain, improvements were observed at W16 & W52 whether inflammation was controlled or not per MRI, CRP, MRI+CRP, or BASDAI 5/6. https://t.co/uHLwFctzPr
      RT @uptoTate: "The strongest single predictor of both telemedicine and electronic patient portal use was English languag

      Dr. Rachel Tate uptoTate

      4 years ago
      "The strongest single predictor of both telemedicine and electronic patient portal use was English language preference." Improving access needs to include barrier awareness of SES and communication issues. Abs 0615 #ACR21 #RheumNow #ACRbest @RheumNow https://t.co/ug4xdWbnST https://t.co/t9DsAVm8aQ
      RT @ericdeinmd: #ACR21 Abs#0834: CorEvitas Registry TNFi vs IL-6 in RA
      ⭐️IL6 pts older, longer h/o RA, higher CDAI,

      Eric Dein ericdeinmd

      4 years ago
      #ACR21 Abs#0834: CorEvitas Registry TNFi vs IL-6 in RA ⭐️IL6 pts older, longer h/o RA, higher CDAI, more prior Rx ▶️ No difference in outcomes bw IL6 and TNFi (monotherapy or combo w MTX). ▶️1/3 of pts achieved LDA Limits: real-world, unblinded https://t.co/AJtzeMuj1T @Rheumnow
      RT @bella_mehta: Single Intraarticular Canakinumab in Knee OA - 18-week randomized, double-blind, double-dummy Placebo a

      Bella Mehta bella_mehta

      4 years ago
      Single Intraarticular Canakinumab in Knee OA - 18-week randomized, double-blind, double-dummy Placebo and naproxen-controlled - effect no different than Placebo. Some efficacy in subgroup with high hsCRP. Need for subtypes in OA @rheumnow #ACR21 #abst0728 https://t.co/YlKTMf56wF
      Novel treatment options for Giant Cell Arteritis

      At this #ACR21, encouraging data will be presented on two such potent

      Dr. John Cush RheumNow

      4 years ago
      Novel treatment options for Giant Cell Arteritis At this #ACR21, encouraging data will be presented on two such potential options for GCA. https://t.co/gyVXHDRXrj @RichardPAConway https://t.co/V2Fg8kCjWy
      psA.fil_.Hands_.jpg
      Guselkumab in Psoriatic Arthritis
      4 years ago
      D1 and D2 trials compared guselkumab vs placebo in patients with active PsA, with the major difference between the two being that only biologic-naïve patients were enrolled in the D2 trial. Today, we discuss three abstracts presented at ACR 2021 that expand on that work with an additional year of data.
      Great Hench Lecture from Peggy Crow at HSS! From LE Cell to Interferon: Deconstructing Lupus Pathogenesis
      #ACR21 https:/

      Dr. John Cush RheumNow

      4 years ago
      Great Hench Lecture from Peggy Crow at HSS! From LE Cell to Interferon: Deconstructing Lupus Pathogenesis #ACR21 https://t.co/rUxiwKGFqm https://t.co/af2PKrFBv3
      RT @Janetbirdope: Obesity does not affect #SLE disease activity despite persistent ⬆️in CRP. From Toronto #lupus dat

      Janet Pope Janetbirdope

      4 years ago
      Obesity does not affect #SLE disease activity despite persistent ⬆️in CRP. From Toronto #lupus database #ACR21 abst#0864 @RheumNow https://t.co/4ZpAMaU0jk
      RT @DrMiniDey: Results from @rheum_covid on #COVID19 outcomes in patients with #vasculitis #Abs0952 #ACR21
      👉🏼~100

      Mrinalini Dey DrMiniDey

      4 years ago
      Results from @rheum_covid on #COVID19 outcomes in patients with #vasculitis #Abs0952 #ACR21 👉🏼~1000 pts 👉🏼Severe outcomes esp in #GCA and #AAV 👉🏼Older age, comorbidities, disease activity, high-dose steroids assoc with worse outcomes @RheumNow https://t.co/e2UlgDpyjw https://t.co/skoTKVYbEL

      Podcasts

      • Giant Cell Arteritis and Polymyalgia Rheumatic Wrapup: Drs. Calabrese, Liew, Conway and Mackie 00:20:18
      • Reproductive Health in Rheumatic Diseases: Drs. Bermas, Buyon and Dao 00:20:26
      • The Expert Gout Panel with Drs. Neogi, Saag, Pillinger, Cush and O'Dell 00:35:26

      Catch up on Conference Podcasts

      ×